Follicular Neoplasm/Suspicious for Follicular Neoplasm

  • Rana S. HodaEmail author
  • Rema Rao
  • Theresa Scognamiglio


  • Thyroid FNA is a highly accurate modality for initial assessment of a nodule. A benign result has a negative predictive value (NPV) greater than 95%, and a malignant diagnosis has a positive predictive value (PPV) of 94–96%. But in 15% to 30% of cases, FNA renders an indeterminate diagnosis, leading to a clinical management dilemma.


Hyperplastic/adenomatoid nodule Follicular neoplasm/suspicious for follicular neoplasm Follicular adenoma Follicular carcinoma NIFTP FVPTC Molecular tests Management Parathyroid adenoma Cell blocks Lipoadenoma Hyalinizing trabecular adenoma 

Suggested Reading

  1. 1.
    Absher KJ, Truong LD, Khurana KK, Ramzy I. Parathyroid cytology: avoiding diagnostic pitfalls. Head Neck. 2002;24:157–64.CrossRefGoogle Scholar
  2. 2.
    Ali SZ, Cibas ES. The Bethesda System for reporting thyroid cytopathology; definitions, criteria, and explanatory notes. 2nd ed. Cham: Springer International Publishing AG; 2018.CrossRefGoogle Scholar
  3. 3.
    Ali SZ, Nayar R, Krane JF, Westra WH. Atlas of thyroid cytopathology with histopathologic correlations. New York: Demos Medical Publishing; 2014.Google Scholar
  4. 4.
    Bommanahalli BP, Bhat RV, Rupanarayan R. A cell pattern approach to interpretation of fine needle aspiration cytology of thyroid lesions: a cyto-histomorphological study. J Cytol. 2010;27:127–32. Scholar
  5. 5.
    Brandler TC, Cho M, Wei XJ, Simms A, Levine P, Hernandez O, et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: an interobserver study of key cytomorphological features from a large academic medical centre. Cytopathology. 2019;30:39–45. Scholar
  6. 6.
    Brandler TC, Liu CZ, Cho M, Zhou F, Cangiarella J, Yee-Chang M, et al. Does noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) have a unique molecular profile? Am J Clin Pathol. 2018;150:451–60. Scholar
  7. 7.
    Cibas ES, Ali SZ. The 2017 Bethesda System for reporting thyroid cytopathology. Thyroid. 2017;27:1341–6. Scholar
  8. 8.
    Cibas ES, Baloch ZW, Fellegara G, LiVolsi VA, Raab SS, Rosai J, et al. A prospective assessment defining the limitations of thyroid nodule pathologic evaluation. Ann Intern Med. 2013;159:325–32. Scholar
  9. 9.
    Choong KC, Khiyami A, Tamarkin SW, McHenry CR. Fine-needle aspiration biopsy of thyroid nodules: is routine ultrasound-guidance necessary? Surgery. 2018;164:789–94. Scholar
  10. 10.
    Clark DP, Faquin WC. Thyroid cytopathology. 2nd ed. New York: Springer; 2010.CrossRefGoogle Scholar
  11. 11.
    Damiani D, Suciu V, Vielh P. Cytopathology of follicular cell nodules. Endocr Pathol. 2015;26:286–90. Scholar
  12. 12.
    Daniels GH. Follicular thyroid carcinoma: a perspective. Thyroid. 2018;28:1229–42. Scholar
  13. 13.
    Duncan LD, Forrest L, Law WM Jr, Hubbard E, Stewart LE. Evaluation of thyroid fine-needle aspirations: can ThinPrep be used exclusively to appropriately triage patients having a thyroid nodule? Diagn Cytopathol. 2011;39:341–8. Scholar
  14. 14.
    Faquin WC, Wong LQ, Afrogheh AH, Ali SZ, Bishop JA, Bongiovanni M, et al. Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology. Cancer Cytopathol. 2016;124:181–7. Scholar
  15. 15.
    Faquin WC, Baloch ZW. Fine-needle aspiration of follicular patterned lesions of the thyroid: diagnosis, management, and follow-up according to National Cancer Institute (NCI) recommendations. Diagn Cytopathol. 2010;38:731–9. Scholar
  16. 16.
    Fischer AH, Clayton AC, Bentz JS, Wasserman PG, Henry MR, Souers RJ, et al. Performance differences between conventional smears and liquid-based preparations of thyroid fine-needle aspiration samples: analysis of 47,076 responses in the College of American Pathologists Interlaboratory Comparison Program in non-gynecologic cytology. Arch Pathol Lab Med. 2013;137:26–31. Scholar
  17. 17.
    Godoi Cavalheiro B, Kober Nogueira Leite A, Luongo de Matos L, Palermo Miazaki A, Ientile JM, Kulcsar MA, et al. Malignancy rates in thyroid nodules classified as Bethesda Categories III and IV: retrospective data from a tertiary center. Int J Endocrinol Metab. 2018;16:e12871. Scholar
  18. 18.
    Han K, Ha HJ, Kong JS, Kim JS, Myung JK, Koh JS, et al. Cytological features that differentiate follicular neoplasm from mimicking lesions. J Pathol Transl Med. 2018;52:110–20. Scholar
  19. 19.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133. Scholar
  20. 20.
    Hoda RS. Non-gynecologic cytology on liquid-based preparations: a morphologic review of facts and artifacts. Diagn Cytopathol. 2007;35:621–34.CrossRefGoogle Scholar
  21. 21.
    Hoda RS, VandenBussche C, Hoda SA. Diagnostic liquid-based cytology. New York: Springer; 2017.CrossRefGoogle Scholar
  22. 22.
    Hang JF, Westra WH, Zhou AG, Cooper DS, Ali SZ. The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the rate of malignancy for atypia of undetermined significance subcategories. Cancer Cytopathol. 2018;126:309–16. Scholar
  23. 23.
    Jug RC, Datto MB, Jiang XS. Molecular testing for indeterminate thyroid nodules: performance of the Afirma gene expression classifier and ThyroSeq panel. Cancer Cytopathol. 2018;126:471–80. Scholar
  24. 24.
    Kapur U, Wojcik EM. Follicular neoplasm of the thyroid: vanishing cytologic diagnosis? Diagn Cytopathol. 2007;35:525–8.CrossRefGoogle Scholar
  25. 25.
    Kelman AS, Rathan A, Leibowitz J, Burstein DE, Haber RS. Thyroid cytology and the risk of malignancy in thyroid nodules: importance of nuclear atypia in indeterminate specimens. Thyroid. 2001;11:271–7.CrossRefGoogle Scholar
  26. 26.
    Krauss EA, Mahon M, Fede JM, Zhang L. Application of the Bethesda Classification for thyroid fine-needle aspiration: institutional experience and meta-analysis. Arch Pathol Lab Med. 2016;140:1121–31. Scholar
  27. 27.
    Kiernan CM, Solórzano CC. Bethesda category III, IV, and V thyroid nodules: can nodule size help predict malignancy? J Am Coll Surg. 2017;225:77–82. Scholar
  28. 28.
    Kim HS, Yun KJ. Adenolipoma of the thyroid gland: report of a case with diagnosis by fine-needle aspiration cytology. Diagn Cytopathol. 2008;36:253–6. Scholar
  29. 29.
    Lim JXY, Nga ME, Chan DKH, Tan WB, Parameswaran R, Ngiam KY. Subclassification of Bethesda atypical and follicular neoplasm categories according to nuclear and architectural atypia improves discrimination of thyroid malignancy risk. Thyroid. 2018;28:511–21. Scholar
  30. 30.
    Luu MH, Fischer AH, Stockl TJ, Pisharodi L, Owens CL. Atypical follicular cells with equivocal features of papillary thyroid carcinoma is not a low-risk cytologic diagnosis. Acta Cytol. 2011;55:526–30. Scholar
  31. 31.
    Macias CA, Arumugam D, Arlow RL, Eng OS, Lu SE, Javidian P, et al. A risk model to determine surgical treatment in patients with thyroid nodules with indeterminate cytology. Ann Surg Oncol. 2015;22:1527–32. Scholar
  32. 32.
    Malheiros DC, Canberk S, Poller DN, Schmitt F. Thyroid FNAC: causes of false-positive results. Cytopathology. 2018;29:407–17. Scholar
  33. 33.
    Manimaran D, Karthikeyan TM, Khan DM, Thulasi Raman R. Follicular variant of papillary thyroid carcinoma: cytological indicators of diagnostic value. J Clin Diagn Res. 2014;8:46–8. Scholar
  34. 34.
    Mathur A, Olson MT, Zeiger MA. Follicular lesions of the thyroid. Surg Clin North Am. 2014;94:499–513. Scholar
  35. 35.
    Michael CW, McConnel J, Pecott J, Afify AM, Al-Khafaji B. Comparison of ThinPrep and TriPath PREP liquid-based preparations in nongynecologic specimens: a pilot study. Diagn Cytopathol. 2001;25:177–84.CrossRefGoogle Scholar
  36. 36.
    Nikiforov YE, Biddinger PW, Thompson LD. Diagnostic pathology and molecular genetics of the thyroid. 3rd ed. Philadelphia: Wolters Kluwer; 2020.Google Scholar
  37. 37.
    Persichetti A, Di Stasio E, Guglielmi R, Bizzarri G, Taccogna S, Misischi I, et al. Predictive value of malignancy of thyroid nodule ultrasound classification systems: a prospective study. J Clin Endocrinol Metab. 2018;103:1359–68. Scholar
  38. 38.
    Pu RT, Yang J, Wasserman PG, Bhuiya T, Griffith KA, Michael CW. Does Hürthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration? Diagn Cytopathol. 2006;34:330–4.CrossRefGoogle Scholar
  39. 39.
    Rekhtman N, Buonocore DJ, Rudomina D, Friedlander M, Dsouza C, Aggarwal G, et al. Novel modification of HistoGel-based cell block preparation method: improved sufficiency for molecular studies. Arch Pathol Lab Med. 2018;142:529–35. Scholar
  40. 40.
    Schreiner AM, Yang GC. Adenomatoid nodules are the main cause for discrepant histology in 234 thyroid fine-needle aspirates reported as follicular neoplasm. Diagn Cytopathol. 2012;40:375–9. Scholar
  41. 41.
    Steward DL, Carty SE, Sippel RS, Yang SP, Sosa JA, Sipos JA, et al. Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: prospective blinded multicenter study. JAMA Oncol. 2018. [Epub ahead of print]; Scholar
  42. 42.
    Ustün H, Astarcı HM, Altunkaya C, Yılmaz S, Barın A, Ekici S, et al. Fine-needle aspiration of follicular patterned lesions of the thyroid: diagnosis, management, and follow-up according to thyroid Bethesda system. Acta Cytol. 2012;56:361–9. Scholar
  43. 43.
    Ustun B, Chhieng D, Van Dyke A, Carling T, Holt E, Udelsman R, Adeniran AJ. Risk stratification in follicular neoplasm: a cytological assessment using the modified Bethesda classification. Cancer Cytopathol. 2014;122:536–45. Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.CBLPathRye BrookUSA
  2. 2.Department of Pathology and Laboratory MedicineNew York Presbyterian Hospital, Weill Cornell Medical CollegeNew YorkUSA

Personalised recommendations